Topic Highlight
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Diabetes. Dec 15, 2013; 4(6): 324-338
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.324
Diabetic macular edema: New promising therapies
Hanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi
Hanan N Al Shamsi, Jluwi S Masaud, Nicola G Ghazi, The Vitroretinal Division, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia
Nicola G Ghazi, Department of ophthalmology, the university of virginia, Charlottesville, VA, United States
Author contributions: Shamsi HNA, Masoud JS and Ghazi NG contributed equally to this work.
Correspondence to: Nicola G Ghazi, Associate Professor, MD, Senior Academic Consultant, The Vitreoretinal Division, King Khaled Eye Specialist Hospital, PO Box 7191, Riyadh 11462, Saudi Arabia. nghazi@kkesh.med.sa
Telephone: +966-1-4821234 Fax: +966-1-4829311
Received: December 27, 2012
Revised: March 17, 2013
Accepted: March 23, 2013
Published online: December 15, 2013
Processing time: 357 Days and 23.2 Hours
Core Tip

Core tip: This manuscript concisely reviews most of the new and emerging therapies for diabetic macular edema. It focuses on therapies that have been tested through clinical trials, but also includes therapies that have not. The article focusses on laser therapy, intravitreal anti-vascular endothelial growth factor agents, intravitreal triamcinolone and newer steroid implants, and vitrectomy. It also briefly discusses several other therapeutic approaches that may be available in the near future.